AstraZeneca reported positive topline data from, the Phase 3 FLAURA2 study of TAGRISSO + Chemo combo in patients with Stage IIIB-IIIC or metastatic Stage IV EGFR NSCLC

This combination demonstrated statistically significant and clinically meaningful and strong improvement in progression-free survival

The safety results and the rate of discontinuation due to adverse events were consistent

OS data were immature at the time of analysis

Results support the potential for a new treatment option that builds on the benefit of first-line standard-of-care TAGRISSO monotherapy